Tecentriq

TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who are naïve to anti-PD-L1 or anti-PD-1 therapies and have disease progression during or following platinum-containing chemotherapy.

Clinical Data by Indication

MatCode Approval No.: -1905-V2-3253